CRICKET BOWLING: A TWO-SEGMENT LAGRANGIAN MODEL

In this study, a Lagrangian forward solution of the bowling arm in cricket is made using a two-segment rigid body model, coupled with projectile equations for the free flight of the ball. For given initial arm positions and constant joint torques, the equations are solved numerically to determine the ball speed and arm angle at release so that the ball can land on a predetermined position on the pitch. The model was driven with kinematic data from video obtained from an elite bowler. The model can be analysed in order to study the biomechanics of the bowling arm as well as to quantify the effects of changing input parameters on the trajectory and speed of the ball

Optimising the front foot contact phase of the cricket fast bowling action

Cricket fast bowling is a dynamic activity in which a bowler runs up and repeatedly delivers the ball at high speeds. Experimental studies have previously linked ball release speed and several technique parameters with conflicting results. As a result, computer simulation models are increasingly being used to understand the effects of technique on performance. This study evaluates a planar 16-segment whole-body torque-driven simulation model of the front foot contact phase of fast bowling by comparing simulation output with the actual performance of an elite fast bowler. The model was customised to the bowler by determining subject-specific inertia and torque parameters. Good agreement was found between actual and simulated performances with a 4.0% RMS difference. Varying the activation timings of the torque generators resulted in an optimised simulation with a ball release speed 3.5 m/s faster than the evaluation simulation. The optimised technique used more extended front ankle and knee kinematics, increased trunk flexion and a longer delay in the onset of arm circumduction. These simulations suggest the model provides a realistic representation of the front foot contact phase of fast bowling and is suitable to investigate the limitations of other kinematic or kinetic variables on fast bowling performance

Breath Formate Is a Marker of Airway S-Nitrosothiol Depletion in Severe Asthma

-nitrosothiols (SNOs), a class of endogenous airway smooth muscle relaxants. This deficiency results from increased activity of an enzyme that both reduces SNOs to ammonia and oxidizes formaldehyde to formic acid, a volatile carboxylic acid that is more easily detected in exhaled breath condensate (EBC) than SNOs. We therefore hypothesize that depletion of airway SNOs is related to asthma pathology, and breath formate concentration may be a proxy measure of SNO catabolism. (r = −0.39, p = 0.002, asthmatics only), and positively correlated with the NO-derived ion nitrite (r = 0.46, p<0.0001) as well as with total serum IgE (r = 0.28, p = 0.016, asthmatics only). Furthermore, formate was not significantly correlated with other volatile organic acids nor with inhaled corticosteroid dose.-nitrosothiols

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

What is already known about this topic? Studies suggest that immunocompromised persons who receive COVID-19 vaccination might not develop high neutralizing antibody titers or be as protected against severe COVID-19 outcomes as are immunocompetent persons. What is added by this report? Effectiveness of mRNA vaccination against laboratory-confirmed COVID-19–associated hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%). Vaccine effectiveness varied considerably among immunocompromised patient subgroups. What are the implications for public health practice? Immunocompromised persons benefit from COVID-19 mRNA vaccination but are less protected from severe COVID-19 outcomes than are immunocompetent persons. Immunocompromised persons receiving mRNA COVID-19 vaccines should receive 3 doses and a booster, consistent with CDC recommendations, practice nonpharmaceutical interventions, and, if infected, be monitored closely and considered early for proven therapies that can prevent severe outcomes

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

What is already known about this topic? Previous infection with SARS-CoV-2 or COVID-19 vaccination can provide immunity and protection against subsequent SARS-CoV-2 infection and illness. What is added by this report? Among COVID-19–like illness hospitalizations among adults aged ≥18 years whose previous infection or vaccination occurred 90–179 days earlier, the adjusted odds of laboratory-confirmed COVID-19 among unvaccinated adults with previous SARS-CoV-2 infection were 5.49-fold higher than the odds among fully vaccinated recipients of an mRNA COVID-19 vaccine who had no previous documented infection (95% confidence interval = 2.75–10.99). What are the implications for public health practice? All eligible persons should be vaccinated against COVID-19 as soon as possible, including unvaccinated persons previously infected with SARS-CoV-2